Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Dr Enrico Vanni, a Non-Executive Director of the Company, had on 14th July purchased 1,000,000 ordinary shares of 1 penny each in the Company at 7.9 pence per Ordinary Share.
Following this transaction, Dr Vanni now holds 14,050,000 Ordinary Shares representing 1.02% of the issued share capital of the Company.
The Company further announces that it has today agreed to award the following share options at an exercise price of 8 pence per share:-
| Share Options | Expiry Date | |
| Sanjeev Pandya, CEO | 10,000,000 | 31 July 2020 |
| Nicolas Serandour, CFO | 10,000,000 | 31 July 2020 |
| Tim Lebus, NED | 7,500,000 | 31 July 2020 |
| Michael Bradfield, NED | 20,000,000 | 31 July 2020 |
| Enrico Vanni | 5,000,000 | 31 July 2020 |
The vesting period for the options is three years and is conditional on the integration and testing of the first LIGHT system in Harley Street by the end of 2016 and treatment of patients in 2017.
For further information, please contact:
| Advanced Oncotherapy Plc | www.avoplc.com |
| Sanjeev Pandya, CEO | Tel: +44 20 3617 8728 |
| Nicolas Serandour, CFO | |
| Westhouse Securities (Nomad & Joint Broker) | |
| Antonio Bossi / David Coaten | Tel: +44 20 7601 6100 |
| Beaufort Securities (Joint Broker) | |
| Saif Janjua / Jon Levinson | Tel: +44 20 7382 8300 |
| Walbrook PR (Financial PR & IR) | Tel: +44 20 7933 8780 or avo@walbrookpr.com |
| Paul McManus / Anna Dunphy | Mob: +44 7980 541 893 / Mob: +44 7876 741 001 |